Recursion Pharmaceuticals, Inc.(RXRX) Stock Research - Grey Stern Research

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis

$7.58 (7.21%)

RXRX Financial Performance


Use the table below to view Recursion Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $7.58 -
52 Week Low $5.60 -
52 Week High $15.74 -
Market Cap $2.9 Billion 1/18
Gross Margin 54% 5/18
Profit Margin -100% 15/18
EBITDA margin -377% 14/18
Q3 - 2024 Revenue $26.1 Million 1/18
Q3 - 2024 Earnings -$95.7 Million 18/18
Q3 - 2024 Free Cash Flow -$60.8 Million 17/18
Trailing 4 Quarters Revenue $65.2 Million 1/18
Trailing 4 Quarters Earnings -$377.6 Million 18/18
Quarterly Earnings Growth -3% 9/18
Annual Earnings Growth -17% 13/18
Quarterly Revenue Growth 158% 1/18
Annual Revenue Growth 51% 1/18
Cash On Hand $427.6 Million 1/18
Short Term Debt $16.5 Million 2/18
Long Term Debt $74.2 Million 3/18

Recursion Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Recursion Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/18
PS 44.39 6/18
PB 5.52 1/18
PC 6.77 4/18
Liabilities to Equity 0.38 9/18
ROA -0.52 7/18
ROE -0.72 9/18
Current Ratio 3.60 8/18
Quick Ratio 2.12 9/18
Long Term Debt to Equity 0.14 6/18
Debt to Equity 0.17 6/18
Burn Rate 4.16 2/18
Cash to Cap 0.15 14/18
CCR 0.64 11/18
EV to EBITDA -25.99 18/18
EV to Revenue 39.22 4/18

Company Details

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO: Dr. Christopher C. Gibson

Website: https://www.recursion.com

Address: 41 South Rio Grande Street Salt Lake City, UT

Exchange: NASDAQ Global Select

Industry: Biotechnology

Recursion Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Recursion Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Affimed N.V. AFMD $42.3 Million
CohBar, Inc. CWBR $1.5 Million
AVROBIO, Inc. AVRO $5.2 Million
Hepion Pharmaceuticals, Inc. HEPA $4.4 Million
X4 Pharmaceuticals, Inc. XFOR $63.3 Million
CNS Pharmaceuticals, Inc. CNSP $6.4 Million
Relay Therapeutics, Inc. RLAY $781.7 Million
Inozyme Pharma, Inc. INZY $179.2 Million
Freeline Therapeutics Holdings plc FRLN $28.3 Million
Sana Biotechnology, Inc. SANA $636.3 Million
Ocean Biomedical, Inc. OCEA $24.8 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
eFFECTOR Therapeutics, Inc. EFTR $941
Enveric Biosciences, Inc. ENVB $3.3 Million
Acumen Pharmaceuticals, Inc. ABOS $141.2 Million
Absci Corporation ABSI $361.8 Million
Immix Biopharma, Inc. IMMX $55.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RXRX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 26.1 Million -$95.7 Million
Q2 2024 $ 14.4 Million -$97.5 Million
Q1 2024 $ 13.8 Million -$91.4 Million
Q4 2023 $ 10.9 Million -$93.0 Million
Q3 2023 $ 10.1 Million -$93.0 Million
Q2 2023 $ 11.0 Million -$76.7 Million
Q1 2023 $ 12.1 Million -$60.8 Million
Q4 2022 $ 13.7 Million -$57.5 Million

View All

RXRX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $427.6 Million $726.5 Million $90.6 Million $524.6 Million
Q2 2024 $476.1 Million $775.9 Million $89.9 Million $584.4 Million
Q1 2024 $299.5 Million $557.8 Million $51.0 Million $401.2 Million
Q4 2023 $394.8 Million $653.7 Million $50.7 Million $463.4 Million
Q3 2023 $387.3 Million $630.8 Million $51.5 Million $438.0 Million
Q2 2023 $405.9 Million $666.7 Million $52.9 Million $469.0 Million
Q1 2023 $473.1 Million $627.4 Million $53.1 Million $430.2 Million
Q4 2022 $549.9 Million $701.3 Million $51.0 Million $485.8 Million

View All

RXRX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$60.8 Million -$1.6 Million -$40.3 Million
Q2 2024 -$86.4 Million -$4.2 Million $176.6 Million
Q1 2024 -$109.0 Million -$6.7 Million -$95.3 Million
Q4 2023 $0 $0 $5.2 Million
Q3 2023 -$73.7 Million -$827,000 -$19.6 Million
Q2 2023 -$71.4 Million -$4.0 Million -$65.6 Million
Q1 2023 -$78.7 Million -$5.3 Million -$76.7 Million
Q4 2022 -$52.7 Million -$8.0 Million $94.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions